Redx Pharma PLC ready to “up its game”: ProactiveInvestors Stocktube

ProactiveInvestors Stocktube

Published on Sep 9, 2016

It has been a busy week for Redx Pharma PLC (LON:REDX), the cancer drug developer. Earlier this week it announced that it had hired Quay Pharma to manufacture supplies of its Porcupine inhibitor for a first-in-man clinical trial, set to begin towards the end of the first quarter of next year. On Thursday, it announced what chief executive officer Neil Murray described as “quite a coup”, with the appointment of former AstraZeneca luminary Karl Hård as head of investor relations and corporate communications.

http://www.4-traders.com/REDX-PHARMA-PLC-21685558/

Murray tells Proactive Investors the Porcupine programme remains on track, and outlines what’s in store for the next 24 months.

He also explains what Hård’s role will be and what he brings to the company. “The appointment allows us to, dare I say, step up our game in getting our message across to fund managers and investment analysts”, Murray said.